Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China

BACKGROUND: In this study, we analyze the cost-effectiveness of fruquintinib as third-line treatment for patients with metastatic colorectal cancer in China, especially after a recent price drop suggested by the National Healthcare Security Administration. METHODS: A Markov model was developed to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Zhi, Hou, Xingduo, Huang, Yangmu, Xie, Tong, Hua, Xinyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556971/
https://www.ncbi.nlm.nih.gov/pubmed/33050905
http://dx.doi.org/10.1186/s12885-020-07486-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556971/
https://www.ncbi.nlm.nih.gov/pubmed/33050905
http://dx.doi.org/10.1186/s12885-020-07486-w

Ejemplares similares